Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Cecilia Arana Yi, Constantine S Tam, Srdan Verstovsek
Future Oncology | FUTURE MEDICINE LTD | Published : 2015
CS Tam recieved honorarium from Novartis. S Verstovsek received research funding from Incyte, AstraZeneca, Lilly Oncology, Geron, NS Pharma, Bristol-Myers Squibb, Novartis, Celgene, Gilead, Seattle Genetics, Promedior and Cell Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.Medical writing assistance was provided by Roland Tacke, PhD, CMPP, of Evidence Scientific Solutions and funded by Incyte Corporation.